Acepodia (ROCO:6976) Debt-to-Equity : 0.04 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Acepodia Debt-to-Equity?

Acepodia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$27.83 Mil. Acepodia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$254.08 Mil. Acepodia's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$6,660.51 Mil. Acepodia's debt to equity for the quarter that ended in Jun. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Acepodia's Debt-to-Equity or its related term are showing as below:

ROCO:6976' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04 Med: -0.01 Max: 0.04
Current: 0.04

During the past 4 years, the highest Debt-to-Equity Ratio of Acepodia was 0.04. The lowest was -0.04. And the median was -0.01.

ROCO:6976's Debt-to-Equity is ranked better than
76.5% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6976: 0.04

Acepodia Debt-to-Equity Historical Data

The historical data trend for Acepodia's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acepodia Debt-to-Equity Chart

Acepodia Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.01

-0.04

-0.02

0.04

Acepodia Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			-0.04	N/A	-0.02	0.04	0.04

Competitive Comparison of Acepodia's Debt-to-Equity

For the Biotechnology subindustry, Acepodia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acepodia's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acepodia's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Acepodia's Debt-to-Equity falls into.

Acepodia Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Acepodia's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.361	+	233.45)	/	6434.049
	=	0.04

Acepodia's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(27.83	+	254.079)	/	6660.509
	=	0.04

Acepodia (ROCO:6976) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Acepodia Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Acepodia's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acepodia (ROCO:6976) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acepodia Inc (ROCO:6976) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

17th floor-12, Number 99, Section 1, Xintai 5th Road, Xizhi District, New Taipei, TWN, 22175

Website

https://www.acepodia.com

Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.

Acepodia (ROCO:6976) Headlines

No Headlines